近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D.*, Fan, J.* Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov., 2022. DOI: 10.1158/2159-8290.CD-21-1022 (IF: 39.4)
Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., Xie, D., Zhu, D.* RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. J Exp Clin Canc Res. 2022. DOI : 10.1186/s13046-022-02289-2 (IF: 11.1)
Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D.*, Wang, M.*, Zhu, D.* BCL9 regulates CD226 and CD96 checkpoints in CD8+ T c ells to improve PD-1 response in cancer. Signal Transduct Target Ther, 2021, 6, 313. (5 year IF: 22.1)
Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y., Rosin-Arbesfeld, R., Shi, Y., Zhou, Y., Yang, M., Feng, Y., Jiang, Y., Shao, Z., Yu, K.*, Zhu, D.* BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene, 2021, 40: 2982- 2997. (IF: 9.8)
Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y.*, Zhu, D.* Discovery of a novel, potent, and selective small-molecu le inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy. Br. J. Pharmacol., 2021, 178(13): 2651-2670. (IF: 8.7)
Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q.*, Zhu, D.* RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer. Pharmacol.Res., 2021, 172:105793. (IF: 7. 6)
Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D.*, T-cell-based immunotherapy in colorectal cancer. Cancer Lett., 2021, 498(40): 201-209. (IF., 8.6)
Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y.*, Zhu, D.* Pharmacolo gical inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockad es by modulating Treg cells. Sci. Adv., 2019, 5(5): 1-16. (IF: 14.1)
Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu, C., Treon, S., Dorfman, D., Pinkus, G., Munshi, N., Tassone, P., Marto, J., Anderson, K., Carrasco, R.* The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med., 2015, 21(6): 572-580. (IF: 53.4)
Takada, K.#, Zhu, D.#, Bird, GH. #, Sukhdeol, K., Zhao, J., Mani, M., Lemieux, M., Carrasco, D., Ryan, J., Horst, D., Fulciniti, M., Mushi, NC., Xu, W., Kung, AL., Shivdasani, R., Walensky, L.*, Carrasco, R.* Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling. Sci Transl Med., 2012, 4(148): 1-13. (IF: 17.9 )
京公网安备 11010802027423号